COMMUNIQUÉS West-GlobeNewswire

Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
17/09/2025
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly [...]
Safety Shot Announces Strategic Board Refresh to Align with New Corporate Vision
17/09/2025
Company Appoints New Directors with Deep Expertise in Venture Capital, Financial Due Diligence, and Bitcoin Mining to Guide Next Phase of Growth SCOTTSDALE, AZ, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. ( [...]
Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
17/09/2025
The European Journal of Pediatrics publishes the first-ever multicenter clinical trial results demonstrating that the Vivos DNA appliance — part of the company’s C.A.R.E. line of devices— is both safe and effective for [...]
CDT Executes Cryptocurrency Treasury Reserve Strategy
17/09/2025
Initial digital asset acquisition marks milestone in capital diversification initiative NAPLES, Fla. And CAMBRIDGE, United Kingdom, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT ) (“CDT” or the “ [...]
Intelligent Bio Solutions Provides Update on FDA 510(k) Clearance Process for Intelligent Fingerprinting Drug Screening System
17/09/2025
NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
iPETcertum™ by Claritas, State-of-the-Art Software for Enhancement, Automated Segmentation and Accurate Quantification in PET, PET-CT/MRI Scans, Receives Clearance from Brazilian Regulator ANVISA
17/09/2025
NEW YORK and LONDON and SAO PAULO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Claritas NucMed Tech Brazil S.A. (“Claritas NucMed Brazil”), a subsidiary of UK-based Claritas NucMed Technologies Ltd (“Claritas NucMed”), a company [...]
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
17/09/2025
NEEDHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]

Pages